Australia's most trusted
source of pharma news
Posted 2 July 2025 AM
There have been seven additions to the PBS this month, including two new medicines, a biosimilar, and four expansions for big brands.
Among the newbies is Servier’s first-in-class IDH1 inhibitor Tibsovo, which has been subsidised for the treatment of adults with locally advanced or metastatic cholangiocarcinoma who have previously progressed on chemotherapy and have a confirmed IDH1 mutation. The company won a recommendation for the drug at the November 2024 meeting via the early re-entry pathway.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.